Reply to V. Pitini et al.

Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol (2012) 4.57

Questionable validity of cardiac risk score on the basis of the NSABP B-31 model. J Clin Oncol (2013) 1.39

Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med (2002) 18.61

Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med (2002) 7.66

Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. N Engl J Med (2010) 5.17

Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol (2011) 4.81

Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol (2005) 4.77

Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol (2012) 4.57

Bevacizumab added to neoadjuvant chemotherapy for breast cancer. N Engl J Med (2012) 4.10

Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast cancer. J Clin Oncol (2009) 3.99

Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials. Lancet (2004) 3.98

Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: results from five National Surgical Adjuvant Breast and Bowel Project randomized clinical trials. J Clin Oncol (2004) 3.82

Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five National Surgical Adjuvant Breast and Bowel Project node-positive adjuvant breast cancer trials. J Clin Oncol (2006) 2.83

Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial. Lancet Oncol (2013) 2.59

Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial. J Clin Oncol (2008) 2.55

Overexpression of Glut-1 and increased glucose metabolism in tumors are associated with a poor prognosis in patients with oral squamous cell carcinoma. Cancer (2003) 2.37

Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31. J Natl Cancer Inst (2013) 2.28

Breast cancer adjuvant therapy: time to consider its time-dependent effects. J Clin Oncol (2011) 2.16

Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial. J Clin Oncol (2013) 2.12

A new generalization of Weibull distribution with application to a breast cancer data set. Stat Med (2009) 2.06

Memory impairments with adjuvant anastrozole versus tamoxifen in women with early-stage breast cancer. Menopause (2007) 2.04

Treatment of axillary lymph node-negative, estrogen receptor-negative breast cancer: updated findings from National Surgical Adjuvant Breast and Bowel Project clinical trials. J Natl Cancer Inst (2004) 1.88

Population-based study of competing mortality in head and neck cancer. J Clin Oncol (2011) 1.82

Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents. Breast Cancer Res Treat (2010) 1.65

Amenorrhea from breast cancer therapy--not a matter of dose. N Engl J Med (2010) 1.40

Regression on quantile residual life. Biometrics (2009) 1.25

Evaluation of microtubule-associated protein-Tau expression as a prognostic and predictive marker in the NSABP-B 28 randomized clinical trial. J Clin Oncol (2009) 1.25

Predictors of competing mortality in early breast cancer. Cancer (2010) 1.08

Overexpression of GLUT-1 is associated with resistance to radiotherapy and adverse prognosis in squamous cell carcinoma of the oral cavity. Oral Oncol (2007) 1.02

Rank tests for clustered survival data. Lifetime Data Anal (2003) 1.01

A phase II neoadjuvant trial of sequential nanoparticle albumin-bound paclitaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide in locally advanced breast cancer. Clin Breast Cancer (2010) 1.00

Median tests for censored survival data; a contingency table approach. Biometrics (2012) 0.97

Akt phosphorylation at Ser473 predicts benefit of paclitaxel chemotherapy in node-positive breast cancer. J Clin Oncol (2010) 0.96

What do perceived cognitive problems reflect? J Support Oncol (2008) 0.96

Advances in adjuvant therapy for breast cancer. Clin Adv Hematol Oncol (2006) 0.94

Evaluation of spontaneous propulsive movement as a screening tool to detect rescue of Parkinsonism phenotypes in zebrafish models. Neurobiol Dis (2011) 0.94

Pitfalls of using composite primary end points in the presence of competing risks. J Clin Oncol (2010) 0.92

Low locoregional recurrence rate among node-negative breast cancer patients with tumors 5 cm or larger treated by mastectomy, with or without adjuvant systemic therapy and without radiotherapy: results from five national surgical adjuvant breast and bowel project randomized clinical trials. J Clin Oncol (2006) 0.89

Detection of recurrent oral squamous cell carcinoma by [18F]-2-fluorodeoxyglucose-positron emission tomography: implications for prognosis and patient management. Cancer (2003) 0.89

An isoform of C/EBPβ, LIP, regulates expression of the chemokine receptor CXCR4 and modulates breast cancer cell migration. J Biol Chem (2013) 0.85

Empirical likelihood ratio test for median and mean residual lifetime. Stat Med (2010) 0.84

NSABP B-42: a clinical trial to determine the efficacy of five years of letrozole compared with placebo in patients completing five years of hormonal therapy consisting of an aromatase inhibitor (AI) or tamoxifen followed by an AI in prolonging disease-free survival in postmenopausal women with hormone receptor-positive breast cancer. Clin Breast Cancer (2006) 0.83

Constrained parametric model for simultaneous inference of two cumulative incidence functions. Biom J (2012) 0.80

The attitudes, communication, treatment, and support intervention to reduce breast cancer treatment disparity. Oncol Nurs Forum (2011) 0.79

Clinical and prognostic value of [(18)F]FDG-PET for surveillance of oral squamous cell carcinoma after surgical salvage therapy. Oral Oncol (2005) 0.79

Reporting of cause-specific treatment effects in cancer clinical trials with competing risks: a systematic review. Contemp Clin Trials (2012) 0.77

Should Histologic Grade Be Incorporated into the TNM Classification System for Small (T1, T2) Node-Negative Breast Adenocarcinomas? Patholog Res Int (2010) 0.76

Metastatic HER2-Positive Breast Cancer: Tailoring Treatment Un-'TIL' We Get It Right... Oncology (Williston Park) (2016) 0.75

Low-Fidelity Haptic Simulation Versus Mental Imagery Training for Epidural Anesthesia Technical Achievement in Novice Anesthesiology Residents: A Randomized Comparative Study. Anesth Analg (2016) 0.75

Stationary versus agitated storage of whole blood during acute normovolemic hemodilution. Anesth Analg (2014) 0.75

Variable selection in subdistribution hazard frailty models with competing risks data. Stat Med (2014) 0.75

The Influence of Knee Pain Location on Symptoms, Functional Status, and Knee-related Quality of Life in Older Adults With Chronic Knee Pain: Data From the Osteoarthritis Initiative. Clin J Pain (2016) 0.75

Trastuzumab as single agent therapy for HER2-positive metastatic breast cancer. Onkologie (2010) 0.75

HER2 targeting in early breast cancer: more options and more questions. Oncology (Williston Park) (2014) 0.75

Censored quantile regression for residual lifetimes. Lifetime Data Anal (2011) 0.75

Systemic therapy for HER2-positive early-stage breast cancer. Curr Probl Cancer (2016) 0.75

Gemcitabine/epirubicin/paclitaxel as neoadjuvant chemotherapy in locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group. Clin Breast Cancer (2008) 0.75

Bayesian nonparametric inference on quantile residual life function: Application to breast cancer data. Stat Med (2012) 0.75